trifluoroiodoethane | 20705-05-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机碘化物
• 英文名称: trifluoroiodoethane
• 英文别名: 1,1,2-trifluoro-1-iodoethane；Ethane, trifluoroiodo-
• CAS: 20705-05-9
• 化学式: C₂H₂F₃I
• 分子量: 209.938
• InChiKey: KYLACLGSGDORMW-UHFFFAOYSA-N

物化性质

• 沸点：
  57.7±8.0 °C(Predicted)
• 密度：
  2.169±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  6
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  trifluoroiodoethane 、 2-((2,2,2-trifluoroethyl)thio)ethanol 在 sodium 、 三苯基膦 作用下， 以 四氯化碳 、 乙醇 、 环己烷 、 2-巯基乙醇 为溶剂， 生成 1-chloro-2-(2,2,2-trifluoro-ethylthio)ethane
  参考文献：
  名称：

  2-imino-6-polyfluoroalkoxybenzothiazole derivatives, and pharamaceutical

  摘要：

  式为：##STR1##及其盐，其中R.sub.1代表多氟烷氧基，R.sub.2代表烷基，烯基（3-6 C），[环烷基（3-6 C）]-烷基，氨基甲酰烷基，二烷基氨基甲酰烷基，酰胺基烷基，苯硫基烷基，羟基烷基，氰基烷基，磺酰乙基，N-烷基磺酰乙基，吡啶硫基烷基，吡啶烷基硫基烷基，吡啶磺氧基烷基，炔基（3-6 C），苯基磺氧基烷基，卤代苯基硫基烷基，（2,2,2-三氟乙硫基）烷基，2-二烷基氨基丙基，嘧啶磺氧基烷基，吡啶烷基磺氧基烷基，卤代苯基磺氧基烷基或（2,2,2-三氟乙磺氧基）烷基在治疗与谷氨酸作用有关的医疗状况中是有用的。

  公开号：

  US04980356A1
• 作为产物：
  描述：

  三氟乙烯 在 环丁砜 、 氢碘酸 、 sodium iodide 作用下， 生成 trifluoroiodoethane
  参考文献：
  名称：

  US2023/75839

  摘要：

  公开号：
• 作为试剂：
  描述：

  (4-methyl-2-sulfanylidene-1,3-thiazol-3-yl) (3R,4R,5S)-4-acetamido-5-[(2-methylpropan-2-yl)oxycarbonylamino]-3-pentan-3-yloxycyclohexene-1-carboxylate 在 四(三苯基膦)钯 、 trifluoroiodoethane 、 三乙胺 、 三氟乙酸 、 mercury dichloride 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 18.5h， 生成
  参考文献：
  名称：

  Tamiphosphor monoesters as effective anti-influenza agents

  摘要：

  Oseltamivir is a potent neuraminidase inhibitor for influenza treatment. By replacing the carboxylate group in oseltamivir with phosphonate monoalkyl ester, a series of tamiphosphor derivatives were synthesized and shown to exhibit high inhibitory activities against influenza viruses. Our molecular modeling experiments revealed that influenza virus neuraminidase contains a 371-cavity near the S1-site to accommodate the alkyl substituents of tamiphosphor monoesters to render appreciable hydrophobic interactions for enhanced affinity. Furthermore, guanidino-tamiphosphor (TPG) monoesters are active to the oseltamivir-resistant mutant. TPG monohexyl ester 4e having a more lipophilic alkyl substituent showed better cell permeability and intestinal absorption than the corresponding monoethyl ester 4c, but both compounds showed similar bioavailability. Intranasal administration of TPG monoesters at low dose greatly improved the survival rate of mice infected with lethal dose of H1N1 influenza virus, whereas 4c provided better protection of the infected mice than oseltamivir and other phosphonate congeners by oral administration. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.082

文献信息

• Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient
  申请人：NIHON NOHYAKU CO., LTD.

  公开号：EP0578246A1

  公开（公告）日：1994-01-12

  Isothiazole derivatives represented by general formula (I): wherein R, R¹, Y and Z have the same significances as described in the specification, and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient, are disclosed.

  通式（I）所代表的异噻唑衍生物： 其中R、R¹、Y和Z的含义与说明书中描述的相同，以及制备这些化合物的方法以及包含其作为活性成分的白蚁控制剂也被披露。
• 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzo
  申请人：Merck & Co., Inc.

  公开号：US05658901A1

  公开（公告）日：1997-08-19

  This invention is concerned with novel compounds represented by structural formula I ##STR1## where X and Y are independently hydrogen, chloro, fluoro, bromo, iodo, or trifluoromethyl and n is 0, 1 or 2; R is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy; and the racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers with all isomeric forms and pharmaceutically acceptable salts, hydrates or crystal forms thereof, which are antiarrhythmic agents.

  这项发明涉及由结构式I表示的新化合物##STR1##其中X和Y分别是氢、氯、氟、溴、碘或三氟甲基，n为0、1或2；R为氢、氟、氯、溴、碘、三氟甲基、甲基或甲氧基；以及其外消旋体、对映体混合物、单对映体或单对映体与所有同分异构体形式和药学上可接受的盐、水合物或晶体形式，这些化合物是抗心律失常药物。
• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US05852010A1

  公开（公告）日：1998-12-22

  The present invention is directed to substituted benozdiazepine compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

  本发明涉及替代苯并二氮杂环化合物，其抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼醇化作用。该发明还涉及含有本发明化合物的化疗组合物以及抑制法尼基-蛋白转移酶和致癌基因蛋白Ras的方法。
• Method for treating Meniere's disease
  申请人：Merck & Company, Inc.

  公开号：US05817658A1

  公开（公告）日：1998-10-06

  A method for the treatment of Meniere's disease comprising the administration of a medicament which modulates the IKs channel of the ear and thereby reducing endolymph production.

  一种治疗梅尼埃病的方法，包括给予一种调节耳朵IKs通道的药物，从而减少内淋巴液的产生。
• Pharmaceutical preparation
  申请人：Merck & Company, Inc.

  公开号：US05776930A1

  公开（公告）日：1998-07-07

  A method of preventing, treating, terminating and protecting against cardiac arrhythmias, such as atrial, supraventricular and ventricular ectopy, tachycardia, flutter or fibrillation, including atrial, supraventricular and ventricular arrhythmias resulting from myocardial ischemic injury in a patient in need thereof, comprising administration of a selective I.sub.Ks antagonist and a beta-adrenergic receptor blocking agent, administered in combined therapy either simultaneously, separately or sequentially is presented. Additionally, a pharmaceutical preparation comprising a selective I.sub.Ks antagonist and a beta-adrenergic receptor blocking agent, wherein these compounds are administered simultaneously, separately or sequentially is presented.

  一种预防、治疗、终止和保护心律失常的方法，如心房、上室和室性异位搏动、心动过速、心房扑动或颤动，包括由心肌缺血损伤引起的心房、上室和室性心律失常，该方法包括给予选择性I.sub.Ks拮抗剂和β-肾上腺能受体阻滞剂，以联合疗法的形式同时、分开或依次给药。此外，还提供了一种药物制剂，包括选择性I.sub.Ks拮抗剂和β-肾上腺能受体阻滞剂，这些化合物可以同时、分开或依次给药。